Patents by Inventor Xavier Fradera

Xavier Fradera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230416225
    Abstract: Compounds of the formula I: or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed herein are uses of these compounds in the potential treatment or prevention of an HPK1-associated disease or disorder. Also disclosed herein are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of an HPK1-associated disease or disorder.
    Type: Application
    Filed: November 4, 2021
    Publication date: December 28, 2023
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Abdelghani Achab, David A. Candito, Anthony Donofrio, Xavier Fradera, Shuhei Kawamura, Samuel M. Levi, Bing Li, Anilkumar G. Nair, Alexander Pasternak, Brandon A. Vara, Elsie C. Yu
  • Publication number: 20230399341
    Abstract: Compounds of the following formula (I); or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed herein are uses of these compounds in the potential treatment or prevention of an HPK1-associated disease or disorder. Also disclosed herein are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of an HPK1-associated disease or disorder.
    Type: Application
    Filed: November 4, 2021
    Publication date: December 14, 2023
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: David A. Candito, Joanna L. Chen, Anthony Donofrio, Xavier Fradera, Peter H. Fuller, Shuhei Kawamura, Bing Li, Jongwon Lim, Ping Liu, Joey L. Methot, Anilkumar G. Nair, Alexander Pasternak, Brandon A. Vara, Elsie C. Yu
  • Publication number: 20230265094
    Abstract: Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: June 7, 2021
    Publication date: August 24, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jenny Lorena Rico Duque, Phieng Siliphaivanh, Xavier Fradera, Zachary G. Brill, Jing SU
  • Publication number: 20230159558
    Abstract: Described herein are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, W, X, Y, Z, m, n and p are as defined herein. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: October 25, 2022
    Publication date: May 25, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Abdelghani Abe Achab, Zachary G. Brill, Jenny Lorena Rico Duque, Xavier Fradera, Joey L. Methot, Phieng Siliphaivanh, Jing Su, Brandon A. Vara, Erin F. DiMauro
  • Publication number: 20230008022
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: November 25, 2019
    Publication date: January 12, 2023
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Xianhai Huang, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, Andreas Verras, Li Xiao, Feng Ye, Wensheng Yu, Rui Zhang
  • Patent number: 11498904
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: November 15, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Yongxin Han, Abdelghani Achab, Indu Bharathan, Xavier Fradera, Derun Li, Nunzio Sciammetta, Wensheng Yu
  • Patent number: 11478461
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: October 25, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Liangqin Guo, Hongjun Zhang, Ping Chen, Dane Clausen, Xavier Fradera, Yongxin Han, Shuwen He, Xianhai Huang, Alexander Pasternak, Qinglin Pu, Li Xiao, Feng Ye
  • Publication number: 20220235028
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: June 8, 2020
    Publication date: July 28, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, Yongqi Deng, Hua Zhou, Meredeth A. McGowan, Hongjun Zhang, Wensheng Yu, Brett A. Hopkins, Xavier Fradera, Nunzio Sciammetta
  • Patent number: 11319283
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: May 3, 2022
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Meredeth Ann McGowan, Abdelghani Achab, Xavier Fradera, Yongxin Han, Derun Li, Jongwon Lim, Kun Liu, Nunzio Sciammetta, Catherine M. White, Wensheng Yu, Hongjun Zhang, Hua Zhou
  • Patent number: 11230547
    Abstract: The instant invention provides compounds of formulas Ia and Ib which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: January 25, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Meredeth A. McGowan, Jason D. Katz, Matthew Christopher, Hua Zhou, David James Witter, Chaomin Li, John Lampe, Joey L. Methot, Abdelghani A. Achab, Xavier Fradera, Shimin Xu
  • Patent number: 11208407
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I) Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: December 28, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hua Zhou, Abdelghani Achab, Xavier Fradera, Yongxin Han, Derun Li, Meredeth A. McGowan, Nunzio Sciammetta, David L. Sloman, Wensheng Yu
  • Publication number: 20210393600
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: April 15, 2019
    Publication date: December 23, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Liangqin Guo, Hongjun Zhang, Ping Chen, Dane Clausen, Xavier Fradera, Yongxin Han, Shuwen He, Xianhai Huang, Alexander Pasternak, Qinglin Pu, Li Xiao, Feng Ye
  • Publication number: 20210395240
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: October 28, 2019
    Publication date: December 23, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, David Sloman, Li Xiao, Wensheng Yu, Rui Zhang
  • Publication number: 20210380572
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: October 11, 2019
    Publication date: December 9, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Jongwon Lim, Theodore A. Martinot, Alexander Pasternak, Li Xiao, Wensheng Yu
  • Patent number: 11179389
    Abstract: The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 23, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Meredeth A. McGowan, Jason D. Katz, Hua Zhou, David James Witter, Chaomin Li, Kathryn A. Lipford, Joey L. Methot, Abdelghani A. Achab, Xavier Fradera, Shimin Xu, Jianmin Fu
  • Publication number: 20210330676
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: August 16, 2019
    Publication date: October 28, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dane Clausen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Xianhai Huang, Joseph Kozlowski, Guoqing Li, Jongwon Lim, Theodore A. Martinot, Alexander Pasternak, Nunzio Sciammetta, Andreas Verras, Li Xiao, Wensheng Yu, Rui Zhang
  • Publication number: 20210317091
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an 1DO-associated disease or disorder.
    Type: Application
    Filed: November 9, 2018
    Publication date: October 14, 2021
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Yongxin Han, Abdelghani Achab, Indu Bharathan, Xavier Fradera, Derun Li, Nunzio Sciammetta, Wensheng Yu
  • Patent number: 11111232
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 7, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Catherine M. White, Abdelghani Achab, Indu T. Bharathan, Xavier Fradera, Yongxin Han, Derun Li, Jongwon Lim, Kun Liu, Meredeth Ann McGowan, Nunzio Sciammetta, Wensheng Yu, Hongjun Zhang, Hua Zhou
  • Patent number: 11103493
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 31, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hua Zhou, Xavier Fradera, Yongxin Han, Meredeth A. McGowan, Nunzio Sciammetta, Catherine White, Wensheng Yu
  • Publication number: 20210179607
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: October 29, 2018
    Publication date: June 17, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yongqi Deng, Abdelghani Achab, Bridget A. Becker, David Jonathan Bennett, Indu Bharathan, Xavier Fradera, Craig Gibeau, Yongxin Han, Derun Li, Kun Liu, Qinglin Pu, Sulagna Sanyal, David Sloman, Wensheng Yu, Hongjun Zhang